Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,567.20
(
1.22%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
100.64
(
3.97%
)
Bitcoin
70,459.00
(
-0.62%
)
News Focus
News Focus
Post# of 257273
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: lumpy9200 post# 49401

Tuesday, 07/10/2007 1:54:19 AM

Tuesday, July 10, 2007 1:54:19 AM

Post# of 257273
> I no longer own a single share. LAR concerns and the impending Liraglutide have scared me off, along with a lofty valuation. I'm curious to know if you have any thoughts on Liraglutide vs. Byetta LAR.<

Liraglutide—as well as NVO itself—appears to be formidable competition. Given the valuation, I cannot fault your decision to take profits on AMLN. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today